Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

89.94USD
12:27pm EDT
Change (% chg)

$0.71 (+0.80%)
Prev Close
$89.23
Open
$89.27
Day's High
$90.07
Day's Low
$88.81
Volume
83,489
Avg. Vol
405,083
52-wk High
$102.43
52-wk Low
$73.60

Latest Key Developments (Source: Significant Developments)

Biomarin Q1 GAAP loss per share $0.09
Thursday, 4 May 2017 04:02pm EDT 

May 4 (Reuters) - Biomarin Pharmaceutical Inc ::Biomarin announces first quarter 2017 financial results.Q1 GAAP loss per share $0.09.Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Q1 revenue $304 million versus I/B/E/S view $288.9 million.Biomarin Pharmaceutical- as of march 31, 2017, had cash, cash equivalents and investments totaling $1.2 billion, versus $1.4 billion on december 31, 2016.Biomarin pharmaceutical inc - 2017 financial guidance is unchanged.  Full Article

Biomarin says Brineura U.S. annual price $486,000
Thursday, 27 Apr 2017 04:56pm EDT 

April 27 (Reuters) - Biomarin Pharmaceutical Inc :Biomarin Pharmaceuticals says expects to begin shipping just approved Brineura within 6 weeks.Biomarin says expected annual cost for Brineura to be $486,000 for ultra-rare pediatric brain disease.Biomarin says will have co-pay program to assist with out-of-pocket cost of brineura.  Full Article

U.S. FDA says granted approval of Brineura to Biomarin Pharmaceutical
Thursday, 27 Apr 2017 01:15pm EDT 

April 27 (Reuters) - U.S. Food and Drug Administration : :FDA approves first treatment for a form of batten disease.Granted approval of Brineura to Biomarin Pharmaceutical Inc.Will require Biomarin Pharmaceutical Inc to further evaluate the safety of Brineura in CLN2 patients below the age of 2 years.  Full Article

Biomarin announces Kuvan patent challenge settlement
Thursday, 13 Apr 2017 08:30am EDT 

Biomarin Pharmaceutical Inc : Biomarin announces Kuvan (sapropterin dihydrochloride) patent challenge settlement . Biomarin Pharmaceutical Inc - retains exclusive U.S. rights until October 1, 2020 .Biomarin Pharmaceutical Inc - under settlement, Biomarin will grant par a non-exclusive license to its patents related to Kuvan.  Full Article

Biomarin reports Q4 GAAP loss per share $0.53
Thursday, 23 Feb 2017 04:01pm EST 

Biomarin Pharmaceutical Inc : Biomarin announces fourth quarter and full year 2016 financial results . Q4 GAAP loss per share $0.53 . Q4 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S . Qtrly total biomarin revenue $300 million versus $228 million . Sees FY17 total biomarin revenues in range of $1,250 million to $1,300 million . Sees 2017 GAAP net loss $140 million to $180 million . Q4 revenue view $296.0 million -- Thomson Reuters I/B/E/S .Fy2017 revenue view $1.31 billion -- Thomson Reuters I/B/E/S.  Full Article

Jennison Associates Llc reports 5.4 pct passive stake in Biomarin Pharmaceutical
Thursday, 2 Feb 2017 04:46pm EST 

Biomarin Pharmaceutical Inc :Jennison Associates Llc reports 5.4 percent passive stake in Biomarin Pharmaceutical Inc as of Dec 31, 2016- sec filing.  Full Article

Biomarin says receives access to priority medicines regulatory support from EMA
Wednesday, 1 Feb 2017 04:15pm EST 

Biomarin Pharmaceutical Inc :Biomarin receives access to priority medicines (prime) regulatory support from ema for bmn 270 gene therapy in hemophilia a.  Full Article

Biomarin Pharmaceutical enters into a credit agreement
Friday, 2 Dec 2016 04:29pm EST 

Biomarin Pharmaceutical Inc : Biomarin Pharmaceutical Inc - On November 29, 2016, co entered into a credit agreement-SEC filing . Credit agreement provides for up to $100 million in revolving loans, none of which was drawn at closing .Expects to use proceeds of revolving credit facility to finance ongoing working capital needs.  Full Article

BioMarin announces update to Brineura program
Tuesday, 6 Sep 2016 04:05pm EDT 

BioMarin Pharmaceutical Inc : BioMarin announces update to Brineura (cerliponase alfa) program for treatment of CLN2 disease, a form of batten disease . Additional data submitted to BLA following FDA request, PDUFA action date extended to April 27, 2017 . Additional 8 months of treatment (81-week data) show maintenance of efficacy, consistent with previously submitted 48-week data .FDA has not communicated their rationale for declaring submission a major amendment.  Full Article

Biomarin Pharmaceutical announces pricing of public offering of common stock
Tuesday, 9 Aug 2016 09:00am EDT 

Biomarin Pharmaceutical Inc : Biomarin announces pricing of public offering of common stock .Says public offering of 7.50 million common shares priced at $96.00per share.  Full Article

More From Around the Web

BRIEF-Biomarin Q1 GAAP loss per share $0.09

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S